A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Pierre Quartier, Florence Allantaz, Rolando Cimaz, Pascal Pillet, Claude Messiaen, Christophe Bardin, Xavier Bossuyt, Anne Boutten, Jacques Bienvenu, Agnes Duquesne, Olivier Richer, Damien J. Chaussabel, Agnes Mogenet, Jacques Banchereau, Jean Marc Treluyer, Paul Landais, Virginia Pascual

Research output: Contribution to journalArticle

298 Citations (Scopus)

Abstract

Objectives: To assess the efficacy of the interleukin 1 receptor antagonist anakinra in systemic-onset juvenile idiopathic arthritis (SJIA). Methods: A multicentre, randomised, double-blind, placebo-controlled trial was conducted. The primary objective was to compare the efficacy of a 1-month treatment with anakinra (2 mg/kg subcutaneous daily, maximum 100 mg) with a placebo between two groups each with 12 patients with SJIA. Response was defined by a 30% improvement of the paediatric American College of Rheumatology criteria for JIA, resolution of systemic symptoms and a decrease of at least 50% of both C-reactive protein and erythrocyte sedimentation rate compared with baseline. After month 1 (M1), patients taking placebo were switched to anakinra. Secondary objectives included tolerance and efficacy assessment for 12 months, and analyses of treatment effect on blood gene expression profiling. Results: At M1, 8/12 responders were receiving anakinra and 1 responder receiving placebo (p=0.003). Ten patients from the placebo group switched to anakinra; nine were responders at M2. Between M1 and M12, six patients stopped treatment owing to an adverse event (n=2), lack of efficacy (n=2) or a disease flare (n=2). Blood gene expression profiling at enrolment and at 6 months' follow-up showed one set of dysregulated genes that reverted to normal values in the clinical responders and a different set, including interferon (IFN)-inducible genes, that was induced by anakinra. Conclusions: Anakinra treatment is effective in SJIA, at least in the short term. It is associated with normalisation of blood gene expression profiles in clinical responders and induces a de novo IFN signature. Trial Registration Number:NCT00339157.

Original languageEnglish
Pages (from-to)747-754
Number of pages8
JournalAnnals of the Rheumatic Diseases
Volume70
Issue number5
DOIs
Publication statusPublished - May 2011
Externally publishedYes

Fingerprint

Interleukin 1 Receptor Antagonist Protein
Interleukin-1 Receptors
Juvenile Arthritis
Placebos
Gene expression
Blood
Gene Expression Profiling
Interferons
Genes
Patient treatment
Pediatrics
Blood Sedimentation
Therapeutics
Transcriptome
Sedimentation
C-Reactive Protein
Reference Values

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). / Quartier, Pierre; Allantaz, Florence; Cimaz, Rolando; Pillet, Pascal; Messiaen, Claude; Bardin, Christophe; Bossuyt, Xavier; Boutten, Anne; Bienvenu, Jacques; Duquesne, Agnes; Richer, Olivier; Chaussabel, Damien J.; Mogenet, Agnes; Banchereau, Jacques; Treluyer, Jean Marc; Landais, Paul; Pascual, Virginia.

In: Annals of the Rheumatic Diseases, Vol. 70, No. 5, 05.2011, p. 747-754.

Research output: Contribution to journalArticle

Quartier, P, Allantaz, F, Cimaz, R, Pillet, P, Messiaen, C, Bardin, C, Bossuyt, X, Boutten, A, Bienvenu, J, Duquesne, A, Richer, O, Chaussabel, DJ, Mogenet, A, Banchereau, J, Treluyer, JM, Landais, P & Pascual, V 2011, 'A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)', Annals of the Rheumatic Diseases, vol. 70, no. 5, pp. 747-754. https://doi.org/10.1136/ard.2010.134254
Quartier, Pierre ; Allantaz, Florence ; Cimaz, Rolando ; Pillet, Pascal ; Messiaen, Claude ; Bardin, Christophe ; Bossuyt, Xavier ; Boutten, Anne ; Bienvenu, Jacques ; Duquesne, Agnes ; Richer, Olivier ; Chaussabel, Damien J. ; Mogenet, Agnes ; Banchereau, Jacques ; Treluyer, Jean Marc ; Landais, Paul ; Pascual, Virginia. / A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). In: Annals of the Rheumatic Diseases. 2011 ; Vol. 70, No. 5. pp. 747-754.
@article{dcaa961b500e4b20bde1f55eaf78dcaa,
title = "A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)",
abstract = "Objectives: To assess the efficacy of the interleukin 1 receptor antagonist anakinra in systemic-onset juvenile idiopathic arthritis (SJIA). Methods: A multicentre, randomised, double-blind, placebo-controlled trial was conducted. The primary objective was to compare the efficacy of a 1-month treatment with anakinra (2 mg/kg subcutaneous daily, maximum 100 mg) with a placebo between two groups each with 12 patients with SJIA. Response was defined by a 30{\%} improvement of the paediatric American College of Rheumatology criteria for JIA, resolution of systemic symptoms and a decrease of at least 50{\%} of both C-reactive protein and erythrocyte sedimentation rate compared with baseline. After month 1 (M1), patients taking placebo were switched to anakinra. Secondary objectives included tolerance and efficacy assessment for 12 months, and analyses of treatment effect on blood gene expression profiling. Results: At M1, 8/12 responders were receiving anakinra and 1 responder receiving placebo (p=0.003). Ten patients from the placebo group switched to anakinra; nine were responders at M2. Between M1 and M12, six patients stopped treatment owing to an adverse event (n=2), lack of efficacy (n=2) or a disease flare (n=2). Blood gene expression profiling at enrolment and at 6 months' follow-up showed one set of dysregulated genes that reverted to normal values in the clinical responders and a different set, including interferon (IFN)-inducible genes, that was induced by anakinra. Conclusions: Anakinra treatment is effective in SJIA, at least in the short term. It is associated with normalisation of blood gene expression profiles in clinical responders and induces a de novo IFN signature. Trial Registration Number:NCT00339157.",
author = "Pierre Quartier and Florence Allantaz and Rolando Cimaz and Pascal Pillet and Claude Messiaen and Christophe Bardin and Xavier Bossuyt and Anne Boutten and Jacques Bienvenu and Agnes Duquesne and Olivier Richer and Chaussabel, {Damien J.} and Agnes Mogenet and Jacques Banchereau and Treluyer, {Jean Marc} and Paul Landais and Virginia Pascual",
year = "2011",
month = "5",
doi = "10.1136/ard.2010.134254",
language = "English",
volume = "70",
pages = "747--754",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

AU - Quartier, Pierre

AU - Allantaz, Florence

AU - Cimaz, Rolando

AU - Pillet, Pascal

AU - Messiaen, Claude

AU - Bardin, Christophe

AU - Bossuyt, Xavier

AU - Boutten, Anne

AU - Bienvenu, Jacques

AU - Duquesne, Agnes

AU - Richer, Olivier

AU - Chaussabel, Damien J.

AU - Mogenet, Agnes

AU - Banchereau, Jacques

AU - Treluyer, Jean Marc

AU - Landais, Paul

AU - Pascual, Virginia

PY - 2011/5

Y1 - 2011/5

N2 - Objectives: To assess the efficacy of the interleukin 1 receptor antagonist anakinra in systemic-onset juvenile idiopathic arthritis (SJIA). Methods: A multicentre, randomised, double-blind, placebo-controlled trial was conducted. The primary objective was to compare the efficacy of a 1-month treatment with anakinra (2 mg/kg subcutaneous daily, maximum 100 mg) with a placebo between two groups each with 12 patients with SJIA. Response was defined by a 30% improvement of the paediatric American College of Rheumatology criteria for JIA, resolution of systemic symptoms and a decrease of at least 50% of both C-reactive protein and erythrocyte sedimentation rate compared with baseline. After month 1 (M1), patients taking placebo were switched to anakinra. Secondary objectives included tolerance and efficacy assessment for 12 months, and analyses of treatment effect on blood gene expression profiling. Results: At M1, 8/12 responders were receiving anakinra and 1 responder receiving placebo (p=0.003). Ten patients from the placebo group switched to anakinra; nine were responders at M2. Between M1 and M12, six patients stopped treatment owing to an adverse event (n=2), lack of efficacy (n=2) or a disease flare (n=2). Blood gene expression profiling at enrolment and at 6 months' follow-up showed one set of dysregulated genes that reverted to normal values in the clinical responders and a different set, including interferon (IFN)-inducible genes, that was induced by anakinra. Conclusions: Anakinra treatment is effective in SJIA, at least in the short term. It is associated with normalisation of blood gene expression profiles in clinical responders and induces a de novo IFN signature. Trial Registration Number:NCT00339157.

AB - Objectives: To assess the efficacy of the interleukin 1 receptor antagonist anakinra in systemic-onset juvenile idiopathic arthritis (SJIA). Methods: A multicentre, randomised, double-blind, placebo-controlled trial was conducted. The primary objective was to compare the efficacy of a 1-month treatment with anakinra (2 mg/kg subcutaneous daily, maximum 100 mg) with a placebo between two groups each with 12 patients with SJIA. Response was defined by a 30% improvement of the paediatric American College of Rheumatology criteria for JIA, resolution of systemic symptoms and a decrease of at least 50% of both C-reactive protein and erythrocyte sedimentation rate compared with baseline. After month 1 (M1), patients taking placebo were switched to anakinra. Secondary objectives included tolerance and efficacy assessment for 12 months, and analyses of treatment effect on blood gene expression profiling. Results: At M1, 8/12 responders were receiving anakinra and 1 responder receiving placebo (p=0.003). Ten patients from the placebo group switched to anakinra; nine were responders at M2. Between M1 and M12, six patients stopped treatment owing to an adverse event (n=2), lack of efficacy (n=2) or a disease flare (n=2). Blood gene expression profiling at enrolment and at 6 months' follow-up showed one set of dysregulated genes that reverted to normal values in the clinical responders and a different set, including interferon (IFN)-inducible genes, that was induced by anakinra. Conclusions: Anakinra treatment is effective in SJIA, at least in the short term. It is associated with normalisation of blood gene expression profiles in clinical responders and induces a de novo IFN signature. Trial Registration Number:NCT00339157.

UR - http://www.scopus.com/inward/record.url?scp=79953323633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953323633&partnerID=8YFLogxK

U2 - 10.1136/ard.2010.134254

DO - 10.1136/ard.2010.134254

M3 - Article

C2 - 21173013

AN - SCOPUS:79953323633

VL - 70

SP - 747

EP - 754

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 5

ER -